Hints of a Mortality Benefit With TTVR at 2 Years TRISCEND II

Why It Matters

If confirmed, a mortality benefit would shift TTVR from a quality‑of‑life therapy to a hard‑outcome option, influencing heart‑team decisions and payer coverage. The data also highlight safety trade‑offs such as higher pacemaker implantation rates.

Key Takeaways

• TTVR mortality 19.1% vs 44.9% in non‑crossover controls
• Bayesian model shows 19.1% vs 29.4% mortality, P=0.03
• Pacemaker implantation 19.7% in TTVR vs 9.0% in controls
• Severe bleeding drops after year 1 in TTVR group
• 95% of TTVR patients achieve mild or less TR at 2 years

Pulse Analysis

Transcatheter tricuspid valve replacement has emerged as a minimally invasive alternative for patients with severe tricuspid regurgitation, a condition historically managed with high‑risk surgery or medical therapy alone. The TRISCEND II trial, which randomized 400 elderly, predominantly female patients, provides the most mature data set on the procedure’s durability and patient‑reported outcomes. At two years, the Evoque system consistently reduced tricuspid regurgitation to mild or less in roughly 95% of treated individuals, translating into substantial improvements in the Kansas City Cardiomyopathy Questionnaire scores—up to 19.6 points versus 1.9 points for optimal medical therapy.

Beyond symptom relief, the trial’s secondary analyses hint at a survival advantage. A landmark analysis of patients who never crossed over to TTVR showed a 44.9% two‑year mortality, markedly higher than the 19.1% observed in the implanted cohort. Complementary Bayesian modeling, which adjusted for crossover and attrition, reinforced this signal with a statistically significant 10‑percentage‑point mortality reduction. However, the study was not powered for mortality endpoints, and the post‑hoc nature of these analyses limits definitive conclusions. Small subgroup sizes—sometimes fewer than 30 patients—further temper confidence, underscoring the need for larger, longer‑term trials.

Clinicians must weigh the potential longevity benefit against procedural risks. TTVR patients experienced higher pacemaker implantation (19.7% vs 9.0%) and early bleeding events, though bleeding rates fell after the first year. These safety considerations, combined with the still‑emerging evidence of hard‑outcome benefit, suggest that heart‑team discussions should remain individualized, factoring in anatomy, comorbidities, and patient preferences. Ongoing registries and planned larger randomized studies will be critical to validate mortality findings, define optimal patient selection, and solidify TTVR’s role alongside transcatheter edge‑to‑edge repair in the expanding tricuspid intervention landscape.